Amylyx Pharmaceuticals, Inc.
AMLX
Hisse Senetlerindeki Sıralama
#4625
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical... Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Hisse Fiyatı
$26.28
Son senkronizasyon: 2026-10-16
Piyasa Değeri
$3.30B
Değişim (1 gün)
-4.95%
Değişim (1 yıl)
75.79%
Ülke
US
Ticaret Amylyx Pharmaceuticals, Inc. (AMLX)
Kategori
Healthcare
Amylyx Pharmaceuticals, Inc. (AMLX) için EPS
June 2026 itibariyle EPS TTM: $-1.41
Amylyx Pharmaceuticals, Inc. şirketinin en son finansal raporlarına ve hisse senedi fiyatına göre, şirketin mevcut EPS'si (TTM) $-1.41'dir. 2023 yılı sonunda, şirketin EPS'si $0.73 idi; bu, 2022 yılındaki EPS olan $-2.98 ile önceki yıla göre artış.
Amylyx Pharmaceuticals, Inc. için 2019 - 2026 arasındaki EPS geçmişi
Her yıl sonunda EPS
| Yıl | EPS | Değiştir |
|---|---|---|
| 2026 (TTM) | $-1.41 | -68.17% |
| 2024 | $-4.43 | -706.85% |
| 2023 | $0.73 | -124.50% |
| 2022 | $-2.98 | 96.05% |
| 2021 | $-1.52 | 92.41% |
| 2020 | $-0.79 | 203.85% |
| 2019 | $-0.26 | 0.00% |
Benzer şirketler veya rakipler için EPS
| Şirket | EPS | EPS Farkı | Ülke |
|---|---|---|---|
| $17.32 | -1,328.37% |
US
|
|
| $-7.98 | 465.96% |
US
|
|
| $-5.29 | 275.18% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -2,067.38% |
NL
|
